Local production of medical technologies and its effect on access in low and middle income countries: A systematic review of the literature

Southern Med Review

Volumn 4, Issue 2, 2011, Pages 4-14

  Kaplan, Warren Allan ^a   Ritz, Lindsay Sarah ^a,b   Vitello, Marie ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Access to medicines; Industrial policy; Pharmaceutical policy; Pharmaceuticals

Indexed keywords

CAPITAL; COST CONTROL; DEVELOPING COUNTRY; DRUG COST; DRUG MANUFACTURE; DRUG QUALITY; EVIDENCE BASED PRACTICE; GROSS NATIONAL PRODUCT; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE POLICY; INVESTMENT; LOCAL PRODUCTION; LOWEST INCOME GROUP; MEDICAL TECHNOLOGY; PATENT; PRODUCT DEVELOPMENT; REVIEW; STRATEGIC PLANNING; SYSTEMATIC REVIEW;

EID: 83055170645     PISSN: 11742704     EISSN: None     Source Type: Journal    
DOI: 10.5655/smr.v4i2.1002     Document Type: Review

References (53)

1. Kaplan W, Laing R. Local production of pharmaceuticals: industrial policy and access to medicines: an overview of key concepts, issues and opportunities for future research. Health, Nutrition and Population Discussion Paper 2005; World Bank, Washington DC, http://siteresources.worldbank.orgHEALTHNUTRITIONANDPOPULATION/Resources/281627-1095698140167 KaplanLocalProductionFinal.pdf (Accessed1 August 2011).
2. Galvao J. Access to antiretroviral drugs in Brazil. The Lancet 2002; 360: 1862-1865.
3. do Lago RF, Costa N do R. Antiretroviral manufacturers and the challenge of universal access to drugs through the Brazilian national STD/AIDS Program. Cad Saúde Pública, Rio de Janeiro 2009; 25: 2273-2284.
4. Ford N et al. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS 2007; 21(Suppl 4): S21-S29.
5. Chaudhuri S. The WTO and India's pharmaceuticals industry: patent protection, TRIPS, and developing countries. New York, New Delhi: Oxford University Press, 2005.
6. Chaudhuri, S. The gap between successful innovation and access to its benefits: Indian pharmaceuticals. Euro J Dev Res 2007; 19: 49-65.
7. Guimier J-M et al. The evidence base for domestic production and greater access to medicines. 2004; DFID Heath Systems Resource Centre, London, http://www.hlsp.org/LinkClick.aspx?fileticket=-wnRCJ0AhQs%3D&tabid=1643 (Accessed 22 August 2011).
8. Bate R. Local Pharmaceutical production in developing countries. Campaign for fighting diseases. 2008; International Policy Press, London WC2E 8HA UK, http://www.libinst.ch/publikationen/LILocalPharmaceuticalProduction.pdf (Accessed 22 August 2011).
9. Liebig K. Auswirkungen des internationalen patentregimes auf die medikamentenproduktion und den zugang zu medikamenten in LDC's. 2006; German Development Institute Bonn, Germany, http://www.unido.org/fileadmin/user_media/Services/PSD/BEP/DIE-GDI.pdf (Accessed 16 August 2011).
10. Attridge CJ, Preker A. Improving access to medicines in developing countries. Health, Nutrition and Population Discussion Paper 2005; World Bank, Washington, D.C, http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/Resources/281627-1095698140167/AttridgeImprovingAccess Final.pdf (Accessed 29 June 2011).
11. Harper J, Gyansa-Lutterordt M. The viability of pharmaceutical manufacturing in Ghana to address priority endemic diseases in the West Africa sub-region. 2007; Deutsche Gesellschaft für Technische Zusammenarbeit GmbH, Eschborn, http://www.unido.org/fileadmin/user_media/Services/PSD/BEP/002_enviability-pharmaceutical-manufacturing-ghana-2007.pdf (Accessed 16 August 2011).
12. Losse K et al. The viability of local pharmaceutical production in Tanzania. 2005; Deutsche Gesellschaft für Technische Zusammenarbeit GmbH, Eschborn, avalailable at http://www.unido.org/fileadmin/user_media/Services/PSD/BEP/Tanzania.pdf (Accessed 12 July 2011).
13. Pokorski da Cunha U. Study on the viability of high quality drugs manufacturing in Bangladesh. 2007; Deutsche Gesellschaft für Technische Zusammenarbeit GmbH, Eschborn, http://www.unido.org/fileadmin/user_media/Services/PSD/BEP/en-highquality-drugs-bangladesh-2007.pdf (Accessed 15 August 2011).
14. Chiwandamira DP, Kamanzi D. Analysis of legal aspects of local pharmaceutical production in Rwanda. 2006; Deutsche Gesellschaft für Technische Zusammenarbeit GmbH, Eschborn, http://www.unido.org/fileadmin/user_media/Services/PSD/BEP/Rwanda.pdf (Accessed 15 August 2011).
15. African Union. Pharmaceutical manufacturing plan for Africa. 2007; http://www.unido.org/fileadmin/user_media/Services/PSD/BEP/Pharmaceutical%20manufacturing%20plan%20for%20Africa-English.pdf (Accessed 10 August 2011).
16. SADC Secretariat. SADC pharmaceutical business plan 2007-2013. 2007; http://www.unido.org/fileadmin/user_media/Services/PSD/BEP/SADC%20PHARMACEUTICAL%20BUSINESS%20PLAN%20-APPROVED%20PLAN.pdf (Accessed 16 August 2011).
17. WHO global strategy and plan of action on public health, innovation and intellectual property: the contribution of Switzerland, Swiss Confederation. 2011; www.deza.admin.ch/ressources/resource_en_200711.pdf(Accessed 16 August 2011)
18. WHO project on improving access to medicines in developing countries through local production and related technology transfer, 2011; World Health Organization, Geneva, Switzerland, http://www.who.int/phi/implementation/TotLCProject.pdf (Accessed 16 August 2011).
19. Mercurio B. Health in the developing world: the case for a new international funding and support agency. Asian J WTO & Int'l Health L. & Pol'y 2009; 27: 1-29.
20. World Health Organization. Medical devices: managing the mismatch. 2010. Geneva, Switzerland, http://whqlibdoc.who.int/publications/2010/9789241564045_eng.pdf (Accessed 15 August 2011)
21. The World Bank. How we classify countries. The World Bank Group, Washington, DC, USA, http://data.worldbank.org/about/country-classifications (Accessed 15 August 2011).
22. Dunning JH. The eclectic paradigm of international production: a restatement and some possible extensions. J Int'l Bus Studies 1988; 19: 1-31.
23. Dunning JH, Lundan SM. Multinational enterprises and the global economy, Second Edition. UK and Massachusetts: Edward Elgar Publishing, 2008.
24. Markusen JR, Maskus KE. Discriminating among alternative theories of the multinational enterprise. 1991; http://www.columbia.edu/~dew35/PDF%20files/Markusen%20and%20Maskus%20Text1.pdf (Accessed 29th June 2011)
25. Caves RE. Multinational enterprise and economic analysis, New York: Cambridge University Press, 2007.
26. Kirim AS. Transnational corporations and local capital: comparative conduct and performance in the Turkish pharmaceutical industry. World Dev 1986; 14: 503-521, http://www.sciencedirect.com/science/article/pii/0305750X86900665 (Accessed 2nd July 2011).
27. Saranga H, Phani BV. Determinants of operational efficiencies in the Indian pharmaceutical industry. Int'l Trans in Op Res 2009; 16: 109-130, http://onlinelibrary.wiley.com/doi/10.1111/j.1475-3995.2009.00668.x/pdf (Accessed 12 July 2011).
28. Ahmed S. Financial performance and characteristics of pharmaceutical and chemical industry in Bangladesh: multinational versus domestic corporations. Independent University, Bangladesh, 2008 [Bachelor of Business Administration], www.sb.iub.edu.bd/Internship_Report_by_Shoeb_Ahmed.pdf (Accessed 1 August 2011)
29. Mackintosh M, Mujinja PGM. Pricing and competition in essential medicines markets: the supply chain to Tanzania and the role of NGOs. IKD Working Paper No. 32. 2008; Open University Research Centre on Innovation Knowledge and Development, http://www.open.ac.uk/ikd/projects_lowcostdrugs.shtml. (Accessed 12 July 2011).
30. Chaudhuri S et al. Indian generics producers, access to essential medicines and local production in Africa: an argument with reference to Tanzania. Euro J Development Res 2010; 22: 451-468.
31. Nunn AS et al. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med 2007; 4: 1804-1817, http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0040305&ct=1. (Accessed 12 August 2011).
32. Chaudhuri S et al. Estimating the effects of global patent protection in pharmaceuticals: A case study of quinolones in India. Amer Econ Rev 2006; 1477-1514.
33. Shafie AA, Hassali MA. Price comparison between innovator and generic medicines sold by community pharmacies in the state of Penang, Malaysia. J Generic Med 2008; 6: 35-42.
34. Chowdury N, Kabir ER. Per pill price differences across therapeutic categories: a study of the essential drug brands marketed by multinational and local pharmaceutical companies in Bangladesh. African J Marketing Mgt 2009; 1: 220-226, http://www.academicjournals.org/ajmm (Accessed 29 June 2011).
35. Kuanpoth J. Patents and access to antiretroviral medicines in Vietnam after World Trade Organization accession, J World Intell Prop 2007; 10: 201-224.
36. Simonet D. The Vietnamese pharmaceutical market: a comparison of foreign entry strategies. Int J Bus and Emerging Mkts 2008; 1: 61-79.
37. Sweileh WM. Substitution of foreign prescribed medicines by community pharmacies in Palestine: a legal and pharmacoeconomic analysis. An-Najah Univ J Nat Sci 2003; 17: 35-41, http://www.najah.edu/page/2147 (Accessed 29 June 2011)
38. Sweileh W et al. Antibiotic drug cost variations in Palestine: physicians and patients dilemma, An-Najah Univ J Nat Sci 2004; 18:73-79.
39. Chaudhuri S. Indian generic companies, affordability of drugs and local production in Africa with special reference to Tanzania. IKD Working Paper No. 37. 2008; Milton Keynes, Open University Research Centre on Innovation Knowledge and Development. http://www.open.ac.uk/ikd/documents/workingpapers/ikd-working-paper-37.pdf (Accessed 22 July 2011).
40. Mackintosh M. Essential medicines supply chains and inequality: the need for new indicators from pharma and beyond. Sant'Anna School of Advanced Studies, Pisa, Italy 15-16 May 2010; http://www.innovation-equity.eu/file_upload/maureenmackintosh_presentation.pdf (Accessed 1 August 2011).
41. Maponga C, Ondari C. The quality of antimalarials: a study in selected African countries. 2004; World Health Organization, Geneva, WHO/EDM/PAR/2003.4, http://whqlibdoc.who.int/hq/2003/WHO_EDM_PAR_2003.4.pdf (Accessed 12 July 2011)
42. Orwa JA et al. Influence of manufacturing practices on quality of pharmaceutical products manufactured in Kenya. East Afr. Med. J. 2004; 81: 287-292, http://www.ajol.info/index.php/eamj/article/viewFile/9177/2097 (Accessed 15 August 2011).
43. Haakonsson SJ. Learning by importing in global value chains: upgrading and south to south strategies in the Ugandan pharmaceutical industry. Dev Southern Africa 2009; 26:499-515.
44. Rodrik D et al. eds Handbook of development economics, Vol. 5, New York and London: Elsevier, 2009.
45. Niëns LM et al. Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med 2010; 7(8): e1000333. doi:10.1371/journal.pmed.1000333.
46. Van Mourik MSM et al. Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disorders 2010; 10:25 doi:10.1186/1471-2261-10-25.
47. Kotwani A. Availability, price and affordability of asthma medicines in five Indian states. Int J Tub Lung Dis 13: 574-579, http://www.haiweb.org/medicineprices/news/index.html (Accessed 22 August 2011).
48. WHO Eastern Mediterranean Survey. Medicine prices, availability, affordability and price components: a synthesis report of medicine price surveys undertaken in selected countries of the WHO Eastern Mediterranean Region, WHO EMRO / HAI, http://www.emro.who.int/dsaf/dsa964.pdf (Accessed 13 August 2011)
49. Cameron A et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The Lancet 2008; doi: 10.1016/S0140-6736(08)6176-6, http://www.haiweb.org/medicineprices/news/31122008/MedPrices%20-%20Word2.pdf (Accessed 16 August 2011).
50. Soumerai SB et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood 2008; 3:185-195.
51. Zhang F et al. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J Clin Epidemiol 2009; 2:143-148.
52. Ledford H. Drug shortage slows clinical trials: US researchers faced with cancer-drug shortfall struggle to keep trials on track. Nature News 2011: published online 3 October 2011, doi:10.1038/news.2011.570, http://www.nature.com/news/2011/111003/full/news.2011.570.html.
53. American Society of Health System Pharmacists. Website: Drug Shortages-Current Drugs, http://www.ashp.org/DrugShortages/Current/.